CTOs on the Move

Vascular Therapies

www.vasculartx.com

 
Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Vascular Therapies raised $17.3M on 01/29/2020
Vascular Therapies raised $23.9M on 03/04/2022

Similar Companies

Pharmaceutical Buyers

Pharmaceutical Buyers is a Cedarhurst, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QRxPharma Limited

QRxPharma Limited is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

egb Advisors

egb Advisors is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PRC

PRC is a global leader in AAC Solutions including for individuals with speech disorders. *This group does not provide official technical support.

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ to improve the ability of the cellular immune system to recognize and destroy diseased cells.